Turning Point Therapeutics (Turning Point Therapeutics) Book Value per Share : $15.90 (As of Jun. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Turning Point Therapeutics Book Value per Share?

Turning Point Therapeutics's book value per share for the quarter that ended in Jun. 2022 was $15.90.

During the past 12 months, Turning Point Therapeutics's average Book Value Per Share Growth Rate was -26.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Turning Point Therapeutics's current price is $76.01. Its book value per share for the quarter that ended in Jun. 2022 was $15.90. Hence, today's PB Ratio of Turning Point Therapeutics is 4.78.

During the past 5 years, the highest P/B Ratio of Turning Point Therapeutics was 6.92. The lowest was 1.42. And the median was 3.52.

Turning Point Therapeutics Book Value per Share Historical Data

The historical data trend for Turning Point Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turning Point Therapeutics Book Value per Share Chart

Turning Point Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Book Value per Share

-1.66

-1.74

11.26

22.80

19.25

Turning Point Therapeutics Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Book Value per Share	Get a 7-Day Free Trial														21.61	20.57	19.25	17.95	15.90

Competitive Comparison of Turning Point Therapeutics's Book Value per Share

For the Biotechnology subindustry, Turning Point Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Turning Point Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Turning Point Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Turning Point Therapeutics's PB Ratio falls into.

Turning Point Therapeutics Book Value per Share Calculation

Turning Point Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2021 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(954.43	-	0.00)	/	49.58
	=	19.25

Turning Point Therapeutics's Book Value Per Share for the quarter that ended in Jun. 2022 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(793.02	-	0.00)	/	49.89
	=	15.90

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Turning Point Therapeutics (NAS:TPTX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Turning Point Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Turning Point Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Turning Point Therapeutics (Turning Point Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Turning Point Therapeutics Inc (NAS:TPTX) » Definitions » Book Value per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

10628 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.tptherapeutics.com

Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.

Executives

Paolo Tombesi	officer: EVP & Chief Financial Officer	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Steve M Sabus	officer: SVP & Chief Commercial Officer	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Brian Sun	officer: SVP & General Counsel	C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Mohammad Hirmand	officer: EVP and Chief Medical Officer	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Athena Countouriotis	director, officer: President & CEO	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Siegfried Reich	officer: EVP & Chief Scientific Officer	10505 ROSELLE STREET SAN DIEGO CA 92121
Andrew John Partridge	officer: EVP & Chief Commercial Officer	C/O CENTREXION THERAPEUTICS CORPORATION 200 STATE STREET BOSTON MA 02109
Annette North	officer: EVP, General Counsel & Secty.	C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Mark J Alles	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Van Hoose Kyri K.	officer: Principal Accounting Officer	C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Barbara W. Bodem	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Brian Lee Baker	officer: VP of Finance and Admin.	C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Yi Larson	officer: EVP & Chief Financial Officer	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Jingrong Jean Cui	director, 10 percent owner, officer: Chief Scientific Officer	C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Simeon George	director	161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428